Efectivo Y Equivalentes Cambio Fecha
AbbVie USD 9.39B 4.16B 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Galectin Therapeutics USD 25.6M 2.04M 2024-06
Gilead Sciences USD 7.56B 234M 2025-12
Immunic USD 186.63M 171.15M 2026-03
Incyte USD 4.02B 435.22M 2026-03
Merck USD 5.33B 9.24B 2026-03